Integrin alpha 4 beta 1 詳細
Molecule Name
Integrin alpha-4/beta-1
分子の別称
Integrin alpha 4 beta 1,ITGA4&ITGB1
Drug Development Progress
治験薬の数6
市販薬剤の数3
研究＆開発段階Approved
ターゲットの別称
Integrin alpha4beta1
バックグランド
Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.
Integrin alpha 4 beta 1 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Natalizumab biosimilar (GENERIUM Pharmaceuticals) | GNR-093 | Phase 3 Clinical | Generium Pharmaceuticals | Multiple Sclerosis | 詳細 |
| Avicursen | TV-1102; ATL/TV-1102; ATL-1102; ISIS-107248 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Multiple Sclerosis; Muscular Dystrophy, Duchenne | 詳細 |
| Alintegimod | 7HP349; 7-HP-349; 7HP-349 | Phase 2 Clinical | 7 Hills Pharma LLC | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis | 詳細 |
| LLP2A alendronate | Phase 1 Clinical | University Of California | Bone Diseases; Bone Diseases, Metabolic; Osteonecrosis; Osteoporosis | 詳細 | |
| ABBV-243 | ABBV-243 | Phase 1 Clinical | Abbvie Inc | 詳細 | |
| RBx-7796 | RBx-7796 | Clinical | Sun Pharmaceutical Industries Ltd | Asthma; Rhinitis, Allergic | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | 詳細 |
| Natalizumab biosimilar (Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Multiple Sclerosis; Crohn Disease | Sandoz Inc | 2023-08-24 | Crohn Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 詳細 |
| Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Crohn Disease; Multiple Sclerosis | Biogen Idec | 2004-11-23 | Arthritis, Rheumatoid; Crohn Disease; Demyelinating Diseases; Epilepsies, Partial; Graft vs Host Disease; Ischemic Stroke; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myositis, Inclusion Body | 詳細 |